Trial Profile
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2023
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1; Optic nerve glioma; Plexiform neurofibroma
- Focus Adverse reactions; Therapeutic Use
- Acronyms INSPECT
- 23 Feb 2023 Planned primary completion date changed from 1 Jan 2022 to 1 Aug 2023.
- 11 Nov 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Jan 2022.
- 10 Jun 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Aug 2021.